Celgene Corporation NASDAQ:CELG is reporting this earnings, what to expect.
Celgene Corporation NASDAQ:CELG headquartered in Summit, New Jersey, United States is reporting their earnings on 05/03/2018 before the bell. Street forecast for the quarter ending March 2018 is $1.78.
According to stock market daily analyst this is Lower then same time previous year. Celgene Corporation reported EPS for the same quarter last year was $1.53.
Overview of Celgene Corporation NASDAQ:CELG
At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.
At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients.
There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), triple-negative breast cancer and pancreatic cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies.
|% Change from 52 Week Low|
|% Change from 52 Week High|